Belumosudil Mesylate Patent Expiration
Belumosudil Mesylate is Used for treating chronic graft-versus-host disease in adults and pediatric patients. It was first introduced by Kadmon Pharmaceuticals Llc
Belumosudil Mesylate Patents
Given below is the list of patents protecting Belumosudil Mesylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Rezurock | US12097202 | Methods of administering Belumosudil for treatment of chronic graft versus host disease | Jul 14, 2042 | Kadmon Pharms Llc |
| Rezurock | US11311541 | Treatment of GVHD | Apr 09, 2035 | Kadmon Pharms Llc |
| Rezurock | US8357693 | Pharmacokinetically improved compounds | Jun 20, 2034 | Kadmon Pharms Llc |
| Rezurock | US10183931 | Rho kinase inhibitors | Oct 07, 2033 | Kadmon Pharms Llc |
| Rezurock | US10696660 | Rho kinase inhibitors | Oct 07, 2033 | Kadmon Pharms Llc |
| Rezurock | US9815820 | Rho kinase inhibitors | Oct 07, 2033 | Kadmon Pharms Llc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Belumosudil Mesylate's patents.
Latest Legal Activities on Belumosudil Mesylate's Patents
Given below is the list recent legal activities going on the following patents of Belumosudil Mesylate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Term Extension Certificate | 12 Nov, 2025 | US8357693 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 08 Oct, 2025 | US11311541 |
| Email Notification | 16 Jul, 2025 | US10183931 |
| Email Notification | 16 Jul, 2025 | US8357693 |
| Change in Power of Attorney (May Include Associate POA) | 16 Jul, 2025 | US8357693 |
| Email Notification | 16 Jul, 2025 | US10696660 |
| Mail Patent eCofC Notification | 15 Jul, 2025 | US10183931 |
| Patent eCofC Notification | 15 Jul, 2025 | US10183931 |
| Mail Patent eCofC Notification | 15 Jul, 2025 | US10696660 |
| Patent eCofC Notification | 15 Jul, 2025 | US10696660 |
Belumosudil Mesylate's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Belumosudil Mesylate:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma | M.D. Anderson Cancer Center | NA |
RECRUITING
(Aug 1, 2026)
| PHASE1, PHASE2 |